Archives
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-11
- 2018-10
- 2018-07
-
Based on structure activity relationship
2025-01-02

Based on structure activity relationship of several SARM templates, Ligand Pharmaceuticals chose LGD2226 as their first clinical candidate (Miner et al., 2007). Although LGD2226 demonstrated myo- and osteo-anabolic activity and maintenance of sexual function in various preclinical models, the develo
-
Since all the above vascular and
2025-01-02

Since all the above vascular and glomerular effects contribute to blood pressure regulation, it is expected for 12/15-LOX pathway to play a role in pathogenesis of hypertension (Fig. 6). Indeed, there is evidence for alterations of the 12- and 15LOX enzymes and metabolites both in humans with essent
-
While high fat diet models of insulin resistance are accepta
2025-01-02

While high-fat diet models of insulin resistance are acceptable approaches for the study of pre-diabetes in humans, they are not suitable for modeling progression towards established type2 diabetes. The pattern of activation of the lipoxygenase pathway in pre-clinical models of type2 diabetes has no
-
br Disclosure br Acknowledgments br Introduction Anaplastic
2025-01-02

Disclosure Acknowledgments Introduction Anaplastic lymphoma kinase (ALK), a receptor tyrosine kinase, belongs to the insulin receptor kinase subfamily [1]. Oncogenic activation of ALK is associated with the Quetiapine and progression of multiple human cancer types [2,3], including anaplast
-
gssg mg Gliomas and Aldehyde Dehydrogenase Aldehyde dehydrog
2024-12-31

Gliomas and Aldehyde Dehydrogenase Aldehyde dehydrogenases (ALDHs) are key metabolic enzymes involved in regulation of glycolysis/gluconeogenesis pathways as well as in the detoxification of endogenous and exogenous aldehydes, regulating cell function and homeostasis. ALDHs play important roles in
-
Notably AR and AR signaling can also occur via
2024-12-31

Notably, β2AR and β3AR signaling can also occur via mechanisms independent from G protein [13]. Additionally, the response to GPCR stimulus can be modified by various parameters, including chronic stimulation, cell hypoxia, acidosis, and aging [14], [15], [16]. GRKs have a significant role in the r
-
The finding that OCT is expressed in the
2024-12-31

The finding that OCT3 is expressed in the nucleus accumbens (Gasser et al., 2009) suggests that inhibition of this transporter may underlie previously described effects of glucocorticoids on extracellular DA concentrations and indicates that DA clearance in this region is not mediated exclusively by
-
Numerous studies have reported high
2024-12-31

Numerous studies have reported high glutamate levels in the brains of patients with depression, indicating that the glutamate system plays a crucial role in depression (Sanacora et al., 2004; Kendell et al., 2005; Hashimoto et al., 2007). Furthermore, several clinically effective antidepressant drug
-
Despite these conflicting data about COX
2024-12-31

Despite these conflicting data about COX-2/ER correlations, a large body of evidence supports that elevated COX-2 expression in breast cancer is a constant feature of high stage disease and a predictor of worse outcome. Upregulation of COX-2 protein has been identified in approximately 40% of cases
-
Antioxidative enzymes such as SOD and CAT play
2024-12-31

Antioxidative enzymes such as SOD and CAT play prominent roles in protecting against oxidative stress and extending food freshness due to their ability in scavenging active oxygen species for maintaining cell membrane integrity. Evidence shows that activities of SOD and CAT are positively affected b
-
The evaluation of serum electrolytes e g
2024-12-30

The evaluation of serum electrolytes (e.g.: sodium, potassium, urea, creatinine, and uric acid), liver transaminases, blood counts (e.g. identification of thrombocytopenia, and bilirubin), 24-h urine (in order to monitor proteinuria), and heart rate and lung function of the mother should be performe
-
Under some pathological conditions AT R internalization
2024-12-30

Under some pathological conditions, AT1R internalization is decreased when agonist exposure is prolonged. This weakens or removes the AT1R desensitization effect and leads to AT1R and downstream signal overactivation. AT1R overactivation can result in continued biological effects such as sustained v
-
br Results The newly synthesized leucine ureido derivatives
2024-12-30

Results The newly synthesized leucine ureido derivatives were firstly evaluated for their enzymatic inhibition using porcine kidney APN (Microsomal, Biocol) with bestatin as the positive control (Table 1). One isoleucine ureido derivative 14 and phenylglycine ureido derivative 15 were also synthe
-
The lactam emerged as lead candidate due
2024-12-30

The lactam (6) emerged as lead candidate due to its high selectivity, outstanding potency (against ALK or in clinically known ALK mutants), low in vitro clearance, and low efflux potential. The lactam (6) was selected for further profiling against the resistant ALK mutants. Preclinical rat pharmacok
-
br Development of lorlatinib from crizotinib to
2024-12-30

Development of lorlatinib from crizotinib (1) to a clinical candidate (6) Xalkori (1, PF-02341066, crizotinib), was the first-in-class ALK inhibitor approved by the Unites States Food and Drug Administration (FDA) in 2011 as a first-line treatment for ALK+- NSCLC patients. This section describes
16615 records 36/1108 page Previous Next First page 上5页 3637383940 下5页 Last page